Evidence map›Paper›PMID 32219388›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2020

Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry.

Lucas Boersma, Edward Koźluk, Giampiero Maglia, João de Sousa, Olaf Grebe, Lars Eckardt, Robert B Hokanson, Lauren A Hemingway, Ekaterina Ostern, Hyoung-Seob Park and 8 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02433613 (Postmarket Evaluation of the Phased Radio Frequency Ablation System), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02433613 completednot on this map

Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)

Typeobservational_patient_registrySponsorMedtronic Cardiac Ablation SolutionsRan2015 to 2019Enrolled1,071ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Quality of life before and after catheter ablation (pulmonary vein isolation) for atrial fibrillation: Results from the Netherlands Heart Registration.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026
    Article
  3. Article
  4. Evolution in electrophysiology 100 years after Einthoven: translational and computational innovations in rhythm control of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. 2-year outcomes of phased radiofrequency ablation for atrial fibrillation with the second-generation PVAC Gold ablation catheter.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2022
    Article
  10. Patients' attitude towards a sham-controlled trial on pulmonary vein isolation in atrial fibrillation.Clinical research in cardiology : official journal of the German Cardiac Society · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 10 countries.

Lucas BoersmaDepartment of Cardiology, St. Antonius Ziekenhuis, PO Box 2500, 3430 EM, Nieuwegein, The Netherlands.
Edward KoźlukCardiology Department, Chair and Department of Cardiology, Medical University of Warsaw, Poland.
Giampiero MagliaCardiology Department, Pugliese-Ciaccio Hospital, Catanzaro, Italy.
João de SousaCardiology Department, Centro Hospitalar Lisboa Norte-Hospital de Santa Maria E.P.E., Lisboa, Portugal.
Olaf GrebeCardiology Department, Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany.
Lars EckardtCardiology Department, Universitätsklinikum Münster, Münster, Germany.
Robert B HokansonCardiology Department, Medtronic, Inc.
Lauren A HemingwayCardiology Department, Medtronic, Inc.
Ekaterina OsternCardiology Department, Medtronic, Inc.
Hyoung-Seob ParkCardiology Department, Keimyung University Dongsan Hospital, Daegu, South Korea.
Giovanni RovarisCardiology Department, A.O. Osped. S.Gerardo, Monza, Italy.
Fernando ArribasCardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Christoph ScharfCardiology Department, Hirslanden-Klinik Im Park Zürich, Zürich, Switzerland.
Zoltán CsanádiCardiology Department, University of Debrecen, Debrecen, Hungary.
Ángel ArenalCardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Francesco LaurenziCardiology Department, Ospedale S. Camillo, Rome, Italy.
Martijn KlaverDepartment of Cardiology, St. Antonius Ziekenhuis, PO Box 2500, 3430 EM, Nieuwegein, The Netherlands.
Andreas GoetteCardiology Department, St. Vincenz-Krankenhaus Paderborn, Medizinische Klinik II, Paderborn, Germany.
Medtronic (Ireland) · IESt. Antonius Ziekenhuis · NLAzienda Ospedaliera Pugliese Ciaccio · ITAzienda Ospedaliera San Gerardo · ITBrüderkrankenhaus St. Josef Paderborn · DECentro Hospitalar Lisboa Norte · PTEvangelisches Krankenhaus Düsseldorf · DEHirslanden Klinik Im Park · CHHospital General Universitario Gregorio Marañón · ESHospital Universitario 12 De Octubre · ESKeimyung University · KRMedical University of Warsaw · PLUniversity Hospital Münster · DEUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe GOLD AF Registry has been designed to prospectively assess the population, indications, and outcomes using second-generation phased radiofrequency (RF) ablation (pulmonary vein ablation catheter GOLD) in a global examination of standard-of-care use for the treatment of paroxysmal and persistent atrial fibrillation (AF). METHODS AND

resultsGOLD AF (NCT02433613) is a prospective, observational, multi-centre registry designed to characterize efficacy and safety of phased RF ablation in patients with AF. The primary endpoint was freedom from AF recurrence at 12-month follow-up after a 90-day blanking period. Ancillary objectives include safety, procedural efficiency, and quality of life (QoL). The QoL assessment using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and the European Heart Rhythm Association (EHRA) Score of AF-related symptoms was collected at baseline and 12 months. In total, 1054 patients were included in this analysis (age 60.6, 67.6% male, 26.5% PersAF). Kaplan-Meier estimate of freedom from AF recurrence was 77.7% at 12 months. Peri-procedural device or procedure-related complications were observed in 26 (2.5%) patients, with a low stroke rate of 0.3%. One-year post-ablation, the EHRA AF Symptom score decreased in 68% of patients. The AFEQT score improvement was observed in 88.4% and 90.4% of patients who completed the questionnaire in-person or interviewed by phone at 12 month follow-up, respectively.

conclusionPhased RF ablation for the treatment of paroxysmal and persistent AF demonstrated a 77.7% freedom from AF recurrence at 12 months in addition to a significant reduction in arrhythmia symptoms and clinically meaningful improved QoL. Low peri-procedural complication rate of <3% was reported.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsCathetersFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeRecurrenceRegistriesTreatment OutcomeAtrial fibrillationCatheter ablationElectrophysiologyPhased radiofrequencyPulmonary vein isolationPVAC

Identifiers

PMID32219388
PMCPMC7273334
OpenAlexW3013277131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.